Exenatide vs CagriSema
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Byetta, Bydureon
Exenatide is the original GLP-1 receptor agonist and it came from an unlikely source: the saliva of the Gila monster, a venomous desert lizard. It is a synthetic 39-amino-acid peptide (a copy of the natural exendin-4) sharing about 50% of its sequence with human GLP-1, sold as the twice-daily Byetta (FDA-approved 2005) and the once-weekly Bydureon. It was the first drug to successfully turn the short-lived incretin hormone into a real diabetes therapy.
Also: Semaglutide + Cagrilintide
CagriSema is a once-weekly injectable that pairs two drugs in one shot: semaglutide (a GLP-1 receptor agonist, the molecule behind Ozempic and Wegovy) and cagrilintide (a long-acting amylin analog). It is being developed by Novo Nordisk for obesity and type 2 diabetes, and in 2025 it cleared its phase 3 REDEFINE trials. It is not yet approved by the FDA, though regulatory filings are underway.
Key Comparison Insights
- Exenatide is FDA approved, while CagriSema remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Exenatide has stronger research evidence (FDA Approved) compared to CagriSema (Human Trials).
Detailed Comparison
| Attribute | Exenatide | CagriSema |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Exenatide binds and activates the GLP-1 receptor, triggering glucose-dependent insulin secretion, suppressing excess glucagon, slowing gastric emptying, and increasing satiety. The reason a lizard peptide beat human GLP-1 to market is durability: native GLP-1 is chewed up by the DPP-4 enzyme within about two minutes, while exendin-4 resists that enzyme and circulates with a half-life of roughly 2.4 hours. Endocrinologist John Eng isolated the peptide in the early 1990s after noting the Gila monster could go long stretches without eating while keeping blood sugar stable. The once-weekly Bydureon formulation traps the peptide in slowly dissolving polymer microspheres so a single injection releases drug over days. | The combination works on two different appetite systems at once. Semaglutide mimics GLP-1, a gut hormone that boosts insulin after meals, slows stomach emptying, and signals fullness to the brain. Cagrilintide is a synthetic version of amylin, a hormone co-secreted with insulin from the pancreas, which reduces food intake and reinforces satiety through separate brain circuits in the hindbrain and hypothalamus. The idea, still being characterized, is that hitting GLP-1 and amylin pathways together produces more appetite suppression than either alone. Both components are engineered for slow release so a single weekly dose maintains steady drug levels. |
| Common Dosing | 5-10 mcg twice daily or 2 mg weekly Twice daily (IR) or once weekly (ER) | Limited community data available See research protocols |
| Administration | Subcutaneous injection | Subcutaneous injection weekly |
| Typical Duration | Long-term / chronic use | Long-term use expected |
| Best Time to Take | Before bed or morning (fasted) | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Exenatide is a long-approved drug with a deep human trial record, not an experimental compound. Its development is well documented in the peer-reviewed literature, including a 2012 review in Regulatory Peptides tracing it from Gila monster venom to an approved antidiabetic. In type 2 diabetes trials it lowered HbA1c and produced modest weight loss, with nausea being the most common side effect, usually fading over time. The EXSCEL cardiovascular outcomes trial found once-weekly exenatide was safe for the heart but did not show a statistically significant reduction in cardiovascular events, which is part of why newer agents like semaglutide and dulaglutide have largely overtaken it. There are rare post-marketing reports of acute pancreatitis, and it is not recommended in severe kidney impairment. Overall, strong human evidence, but now considered an older option in the class. | This is one of the better-tested experimental obesity drugs because it went straight into large human phase 3 trials rather than living only in animal data. In REDEFINE 1, about 3,400 adults with overweight or obesity but without diabetes were randomized over 68 weeks; CagriSema produced roughly 20.4% average body weight loss versus 14.9% for semaglutide alone, 11.5% for cagrilintide alone, and 3.0% for placebo, with results published in the New England Journal of Medicine in 2025. REDEFINE 2 tested it in adults with type 2 diabetes and also met its endpoints, showing meaningful weight loss and HbA1c improvement compared with placebo. Notably, the headline 20% figure landed below Novo Nordisk's own 25% target, which disappointed investors even though the drug clearly worked. The most common side effects were gastrointestinal: nausea, vomiting, diarrhea, and constipation, consistent with the GLP-1 plus amylin class. CagriSema is not FDA-approved as of mid-2026, so anything sold under that name outside a clinical setting is unregulated. |
Frequently Asked Questions: Exenatide vs CagriSema
What is the difference between Exenatide and CagriSema?
Exenatide is a weight loss peptide that exenatide is the original glp-1 receptor agonist and it came from an unlikely source: the saliva of the gila monster, a venomous desert lizard. it is a synthetic 39-amino-acid peptide (a copy of the natural exendin-4) sharing about 50% of its sequence with human glp-1, sold as the twice-daily byetta (fda-approved 2005) and the once-weekly bydureon. it was the first drug to successfully turn the short-lived incretin hormone into a real diabetes therapy. CagriSema is a weight loss peptide that cagrisema is a once-weekly injectable that pairs two drugs in one shot: semaglutide (a glp-1 receptor agonist, the molecule behind ozempic and wegovy) and cagrilintide (a long-acting amylin analog). it is being developed by novo nordisk for obesity and type 2 diabetes, and in 2025 it cleared its phase 3 redefine trials. it is not yet approved by the fda, though regulatory filings are underway. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Exenatide or CagriSema?
Neither is universally "better" - the choice depends on your specific goals. Exenatide is typically used for weight loss purposes, while CagriSema is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Exenatide and CagriSema be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Exenatide and CagriSema together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.